SG10201810496XA - Nmda receptor modulators and prodrugs, salts, and uses thereof - Google Patents

Nmda receptor modulators and prodrugs, salts, and uses thereof

Info

Publication number
SG10201810496XA
SG10201810496XA SG10201810496XA SG10201810496XA SG10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA SG 10201810496X A SG10201810496X A SG 10201810496XA
Authority
SG
Singapore
Prior art keywords
prodrugs
salts
compounds
nmda receptor
receptor modulators
Prior art date
Application number
SG10201810496XA
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of SG10201810496XA publication Critical patent/SG10201810496XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG10201810496XA 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof SG10201810496XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28

Publications (1)

Publication Number Publication Date
SG10201810496XA true SG10201810496XA (en) 2018-12-28

Family

ID=53004986

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810496XA SG10201810496XA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof
SG11201603376UA SG11201603376UA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201603376UA SG11201603376UA (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Country Status (15)

Country Link
US (2) US9745342B2 (de)
EP (2) EP3062810A4 (de)
JP (1) JP6603668B2 (de)
KR (1) KR20160077153A (de)
CN (2) CN105764522A (de)
AU (2) AU2014342624A1 (de)
BR (1) BR112016009443A8 (de)
CA (1) CA2928701A1 (de)
CL (2) CL2016001001A1 (de)
IL (1) IL245302B (de)
MX (2) MX2016005510A (de)
RU (1) RU2016119830A (de)
SA (1) SA516371037B1 (de)
SG (2) SG10201810496XA (de)
WO (1) WO2015065891A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014116739A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
CN116082461B (zh) * 2022-10-14 2023-11-14 浙江大学 一种具有抗菌活性的小分子肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263858A1 (en) * 2004-09-14 2009-10-22 Shionogi & Co., Ltd. Process for synthesis of mucin-type peptides and muc1-related glycopeptides
US7960506B2 (en) * 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
ES2648687T3 (es) * 2007-02-23 2018-01-05 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
CN104961795A (zh) * 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP2542254B1 (de) * 2010-02-11 2018-09-26 Northwestern University Nmda-rezeptor-agonisten und ihre verwendungen
EP2701721A4 (de) * 2011-04-27 2015-12-16 Univ Northwestern Verfahren zur behandlung von morbus alzheimer, morbus huntington, autismus oder anderen erkrankungen

Also Published As

Publication number Publication date
US20180127466A1 (en) 2018-05-10
CL2016001001A1 (es) 2016-12-16
CN112321678A (zh) 2021-02-05
IL245302A0 (en) 2016-06-30
JP2016537413A (ja) 2016-12-01
CL2020002247A1 (es) 2021-02-05
IL245302B (en) 2020-05-31
US20160244485A1 (en) 2016-08-25
US9745342B2 (en) 2017-08-29
MX2021000029A (es) 2021-03-25
AU2014342624A1 (en) 2016-06-02
JP6603668B2 (ja) 2019-11-06
EP3062810A1 (de) 2016-09-07
US10590167B2 (en) 2020-03-17
WO2015065891A1 (en) 2015-05-07
BR112016009443A8 (pt) 2020-03-24
AU2020201109A1 (en) 2020-03-05
EP3564256A1 (de) 2019-11-06
MX2016005510A (es) 2017-01-06
KR20160077153A (ko) 2016-07-01
EP3062810A4 (de) 2017-05-03
RU2016119830A (ru) 2017-12-04
CN105764522A (zh) 2016-07-13
RU2016119830A3 (de) 2018-07-02
SA516371037B1 (ar) 2018-05-16
CA2928701A1 (en) 2015-05-07
SG11201603376UA (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PH12015501601A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP2542254A4 (de) Durch eine sekundäre struktur stabilisierte rezeptormodulatoren und anwendungen davon
GEP20207082B (en) Prodrugs of pyridone amides useful as modulators of sodium channels
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
MX2019001308A (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
EP4086249A3 (de) 6-gliedrige heterozyklen mit delta-opioidrezeptor-modulierenden verbindungen, verfahren zur herstellung und verwendung davon
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
MX2021000029A (es) Profarmacos y moduladores de receptores nmda, sales y usos de estos.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
PH12015501538A1 (en) Topical ocular analgesic agents
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.